Class A Ord · CUSIP 61559X104 · who reports it, how much, and how much it matters to them
39 of the 720 hedge fund managers we track reported shares of MoonLake Immunotherapeutics (Nasdaq: MLTX) on Form 13F for 30 June 2026. Between them they reported USD 596m. The largest position belongs to Deep Track Capital, at USD 136m. The manager with the most riding on it is Lion Point Capital, where it is 6.3% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Deep Track Capital1 fund on PPLI.com | USD 136m | 2.0% |
| 2 | D. E. Shaw & Co.15 funds on PPLI.com | USD 66m | 0.0% |
| 3 | Cormorant Asset Management1 fund on PPLI.com | USD 62m | 3.2% |
| 4 | Logos Global Management1 fund on PPLI.com | USD 52m | 2.2% |
| 5 | Weiss Asset Management5 funds on PPLI.com | USD 50m | 0.5% |
| 6 | Citadel Advisors32 funds on PPLI.com | USD 38m | 0.0% |
| 7 | Two Sigma Investments35 funds on PPLI.com | USD 33m | 0.0% |
| 8 | POINT72 Asset Management17 funds on PPLI.com | USD 23m | 0.0% |
| 9 | Balyasny Asset Management25 funds on PPLI.com | USD 18m | 0.0% |
| 10 | Great Point Partners2 funds on PPLI.com | USD 17m | 3.1% |
| 11 | Renaissance Technologies13 funds on PPLI.com | USD 13m | 0.0% |
| 12 | Millennium Management6 funds on PPLI.com | USD 12m | 0.0% |
| 13 | Marshall Wace LLP84 funds on PPLI.com | USD 11m | 0.0% |
| 14 | Capricorn Fund Managers8 funds on PPLI.com | USD 7.3m | 0.6% |
| 15 | Boxer Capital Management1 fund on PPLI.com | USD 5.4m | 0.4% |
| 16 | Burkehill Global Management5 funds on PPLI.com | USD 4.9m | 0.2% |
| 17 | Holocene Advisors2 funds on PPLI.com | USD 4.9m | 0.0% |
| 18 | Walleye Capital8 funds on PPLI.com | USD 4.8m | 0.0% |
| 19 | J. Goldman & Co.1 fund on PPLI.com | USD 4.2m | 0.1% |
| 20 | Acuta Capital Partners2 funds on PPLI.com | USD 4.2m | 2.9% |
| 21 | Verition Fund Management3 funds on PPLI.com | USD 4m | 0.0% |
| 22 | HighVista Strategies27 funds on PPLI.com | USD 3.7m | 0.8% |
| 23 | Voleon Capital Management13 funds on PPLI.com | USD 3.4m | 0.1% |
| 24 | Exome Asset Management2 funds on PPLI.com | USD 3.2m | 2.0% |
| 25 | Engineers Gate Manager1 fund on PPLI.com | USD 2.2m | 0.0% |
| 26 | Polymer Capital Management (HK)1 fund on PPLI.com | USD 2m | 0.1% |
| 27 | Jain Global1 fund on PPLI.com | USD 1.9m | 0.0% |
| 28 | Squarepoint Ops7 funds on PPLI.com | USD 1.7m | 0.0% |
| 29 | Lion Point Capital1 fund on PPLI.com | USD 1.3m | 6.3% |
| 30 | Capital Fund Management S.A.12 funds on PPLI.com | USD 1.3m | 0.0% |
| 31 | Tudor Investment Corporation10 funds on PPLI.com | USD 1.1m | 0.0% |
| 32 | Exoduspoint Capital Management7 funds on PPLI.com | USD 908,000 | 0.0% |
| 33 | Campbell & Company Investment Adviser8 funds on PPLI.com | USD 578,000 | 0.0% |
| 34 | Aquatic Capital Management3 funds on PPLI.com | USD 548,000 | 0.0% |
| 35 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 537,000 | 0.0% |
| 36 | Prelude Capital Management9 funds on PPLI.com | USD 506,000 | 0.0% |
| 37 | Graham Capital Management18 funds on PPLI.com | USD 419,000 | 0.0% |
| 38 | Rock Springs Capital Management2 funds on PPLI.com | USD 208,000 | 0.0% |
| 39 | The Quarry1 fund on PPLI.com | USD 2,336 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Lion Point Capital | USD 1.3m | 6.3% |
| 2 | Cormorant Asset Management | USD 62m | 3.2% |
| 3 | Great Point Partners | USD 17m | 3.1% |
| 4 | Acuta Capital Partners | USD 4.2m | 2.9% |
| 5 | Logos Global Management | USD 52m | 2.2% |
| 6 | Exome Asset Management | USD 3.2m | 2.0% |
| 7 | Deep Track Capital | USD 136m | 2.0% |
| 8 | HighVista Strategies | USD 3.7m | 0.8% |
| 9 | Capricorn Fund Managers | USD 7.3m | 0.6% |
| 10 | Weiss Asset Management | USD 50m | 0.5% |
MoonLake Immunotherapeutics trades under the symbol MLTX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 61559X104.
39 of the 720 hedge fund managers PPLI.com tracks reported MoonLake Immunotherapeutics shares on Form 13F for 30 June 2026. The largest reported positions were held by Deep Track Capital (USD 136m), D. E. Shaw & Co. (USD 66m), Cormorant Asset Management (USD 62m), Logos Global Management (USD 52m) and Weiss Asset Management (USD 50m).
39 managers in our coverage reported it, and between them they run 420 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Lion Point Capital, where the position was 6.3% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with MoonLake Immunotherapeutics or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.